Qiagen has agreed to partner with AstraZeneca to develop a liquid biopsy-based companion diagnostic test to accompany one of the pharmaceutical company's lung cancer drugs.
Building on a master framework agreement signed by both companies in 2013, the partnership will involve the creation of a diagnostic test that analyses plasma samples to assess EGFR mutation status in non-small cell lung cancer patients.